• We specialize in small molecule inhibitors, agonists, antagonists and screening libraries!
Search Site
Home >> Screening Panel >> DiscoveryProbe™ Metabolism-related Compounds Panel
Related Products
DiscoveryProbe™ Metabolism-related Compounds Panel

DiscoveryProbe™ Metabolism-related Compounds Panel

Catalog No. L1013
Size Price Stock Qty
5mg/well $5,430.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Click and Customize the Panel with your own choices of compounds/size/quantities/chemical forms etc.

HTS Facility Partners

Featured Products of the Panel

Catalog No. Product Name Summary Targets CAS Number Smiles
A5143 Finasteride Inhibitor of Type II 5α-reductase Metabolism|5-alpha Reductase 98319-26-7 CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C
A4336 Mycophenolate Mofetil IMPDH inhibitor Metabolism|Dehydrogenase 128794-94-5 CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC
A4365 Lovastatin HMG-CoA reductase inhibitor Metabolism|HMG-CoA Reductase 75330-75-5 CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
B7794 BMS 309403 FABP4 inhibitor,potent and selective Metabolism|Lipid Metabolism 300657-03-8 OC(COC1=CC(C2=CC=CC=C2N3N=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=C3CC)=CC=C1)=O
A4325 PF-2545920 PDE10A inhibitor,potent and selective Metabolism|PDE 1292799-56-4 CN1C=C(C(=N1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C5=CC=NC=C5
A4331 GSK256066 PDE4-inhibitor,selective and highly potent Metabolism|PDE 801312-28-7 CC1=C2C(=CC(=C1)S(=O)(=O)C3=CC=CC(=C3)C(=O)N(C)C)C(=C(C=N2)C(=O)N)NC4=CC(=CC=C4)OC
Download the Metabolism-related Compounds Panel - XLSX       Download the Metabolism-related Compounds Panel - SDF

Quality Control

Related Biological Data

Pemetrexed

Related Biological Data

Pemetrexed

Related Biological Data

AUY922 (NVP-AUY922)

Related Biological Data

AUY922 (NVP-AUY922)

Signaling Pathway

HMG-CoA Reductase Compare Products
PPAR Research Area
PPAR Compare Products
PDE Compare Products

Advantages

  • Available in stock with overnight delivery and free shipping over $500
  • Cost-effective and competitive price to save your findings
  • Potent, selective and cell-permeable in inhibiting or activating target molecules
  • Diverse in chemical structure and route of administration (oral/i.m/i.v injection etc.)
  • Detailed files describing potency, selectivity and applications etc.
  • Supported by published data from top peer-reviewed journals
  • Guaranteed high quality with NMR and HPLC validation

Storage and Shipping Information

Solubility Soluble in DMSO Storage Desiccate at -20°C
Packaging 96 well plate Form Powder
General tips For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

A wide range of well-characterized bioactive molecules that covers various targets related to metabolism, including PPAR, HMG-CoA reductase, HSP, PDE and DHFR etc. Facilitate your research towards the insights of diabetes, hypertension ad hormone regulation etc. Applicable in cellular assays, animal models and drug screenings etc.

References

1. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013 May;19(5):557-66.
Abstract
Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) and are highly effective oral medications for type 2 diabetes. Recent studies that have supported the continuing physiologic and therapeutic relevance of the PPARγ pathway also provide opportunities to develop newer classes of molecules that reduce or eliminate adverse effects. This review highlights key advances in understanding PPARγ signaling in energy homeostasis and metabolic disease and also provides new explanations for adverse events linked to TZD-based therapy.